Education
About Us
Working with TipRanks
Follow Us
Monopar Therapeutics Inc (MNPR)
NASDAQ:MNPR
MNPR Analyst Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MNPR Stock 12 Month Forecast
Average Price Target
$108.75
▲(58.46% Upside)
| Highest Price Target$130.00 | Average Price Target$108.75 | Lowest Price Target$85.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
JonesTrading
$130
Buy
89.42%
Upside
Reiterated
12/15/25
Oppenheimer
$115
Buy
67.57%
Upside
Reiterated
11/14/25
BTIG
$104
Buy
51.54%
Upside
Reiterated
11/14/25
H.C. Wainwright
$105
Buy
52.99%
Upside
Reiterated
11/14/25
Raymond James
$142→$123
Buy
79.22%
Upside
Reiterated
11/14/25
Barclays
$125
Buy
82.14%
Upside
Reiterated
11/13/25
Leerink Partners
$115
Buy
67.57%
Upside
Initiated
11/10/25
Piper Sandler
$95
Buy
38.42%
Upside
Reiterated
11/10/25
Lake Street
$106
Buy
54.45%
Upside
Reiterated
11/10/25
Cantor Fitzgerald
$109
Buy
58.82%
Upside
Reiterated
11/04/25
Chardan Capital
$60→$85
Buy
23.85%
Upside
Reiterated
09/25/25
Brookline Capital Markets
$52→$93
Buy
35.51%
Upside
Reiterated
09/25/25
Lucid Capital
$71
Buy
3.45%
Upside
Initiated
06/05/25
Citi
$40
Buy
-41.72%
Downside
Reiterated
03/31/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
JonesTrading
$130
Buy
89.42%
Upside
Reiterated
12/15/25
Oppenheimer
$115
Buy
67.57%
Upside
Reiterated
11/14/25
BTIG
$104
Buy
51.54%
Upside
Reiterated
11/14/25
H.C. Wainwright
$105
Buy
52.99%
Upside
Reiterated
11/14/25
Raymond James
$142→$123
Buy
79.22%
Upside
Reiterated
11/14/25
Barclays
$125
Buy
82.14%
Upside
Reiterated
11/13/25
Leerink Partners
$115
Buy
67.57%
Upside
Initiated
11/10/25
Piper Sandler
$95
Buy
38.42%
Upside
Reiterated
11/10/25
Lake Street
$106
Buy
54.45%
Upside
Reiterated
11/10/25
Cantor Fitzgerald
$109
Buy
58.82%
Upside
Reiterated
11/04/25
Chardan Capital
$60→$85
Buy
23.85%
Upside
Reiterated
09/25/25
Brookline Capital Markets
$52→$93
Buy
35.51%
Upside
Reiterated
09/25/25
Lucid Capital
$71
Buy
3.45%
Upside
Initiated
06/05/25
Citi
$40
Buy
-41.72%
Downside
Reiterated
03/31/25
Best Analysts Covering Monopar Therapeutics Inc
1 Month
xxx
Success Rate
3/5 ratings generated profit
Average Return
+43.76%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +43.76% per trade.
3 Months
xxx
Success Rate
3/5 ratings generated profit
Average Return
+68.34%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +68.34% per trade.
1 Year
Success Rate
3/5 ratings generated profit
Average Return
+43.16%
reiterated a buy rating last month
Copying Biren Amin's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +43.16% per trade.
2 Years
xxx
Success Rate
4/4 ratings generated profit
Average Return
+129.55%
initiated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +129.55% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MNPR Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
5
7
6
6
3
Buy
1
10
16
25
16
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
17
22
31
19
Each month's total comprises the sum of three months' worth of ratings.
MNPR Financial Forecast
MNPR Stock Forecast FAQ
What is MNPR’s average 12-month price target, according to analysts?
Based on analyst ratings, Monopar Therapeutics Inc’s 12-month average price target is 108.75.
What is MNPR’s upside potential, based on the analysts’ average price target?
Monopar Therapeutics Inc has 58.46% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MNPR a Buy, Sell or Hold?
Monopar Therapeutics Inc has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
What is Monopar Therapeutics Inc’s price target?
The average price target for Monopar Therapeutics Inc is 108.75. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $130.00 ,the lowest forecast is $85.00. The average price target represents 58.46% Increase from the current price of $68.63.
The highest analyst price target is $130.00 ,the lowest forecast is $85.00. The average price target represents 58.46% Increase from the current price of $68.63.
What do analysts say about Monopar Therapeutics Inc?
Monopar Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of MNPR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.